Real-time tissue analysis gives Mayo Clinic much lower reoperation numbers than national rate
Unique laboratory testing during breast cancer lumpectomies to make sure surgeons remove all cancerous tissue spares patients the need for a repeat lumpectomy in roughly 96 percent of cases at Mayo Clinic in Rochester, a success rate much higher than the rate nationally, a Mayo study shows.
During the years reviewed, 13.2 percent of breast cancer lumpectomy patients nationally had to return to the operating room within a month of their initial surgery, compared to 3.6 percent at Mayo in Rochester, which uses a technique called frozen section analysis to test excised tissue for cancer while patient are still on the operating table. The findings are published in the journal Surgery.
In breast cancer lumpectomies, surgeons remove tumors with a small amount of normal tissue around them to help ensure they excised all of the cancer. This is known as obtaining “clean” or “negative” margins. During surgery at Mayo in Rochester, that tissue is transferred from the operating room to a nearby pathology lab, where the edges around the lumpectomy are shaved and each sample is frozen and reviewed under a microscope by a pathologist, all within minutes, while the patient is still anesthetized.
The pathologist immediately gives the surgeon the results, so the surgeon knows whether the lumpectomy is complete or there is still cancerous tissue to remove, and at which margin, before the operation concludes.
Mayo Clinic remains one of the only U.S. medical centers to perform frozen section analysis, and its process is unique, including use of a Mayo-modified microtome to freeze tissue so the pathologist can get a 360-degree view around the lumpectomy cavity.
“This intense pathological evaluation with the use of frozen section of the margins while the patient is asleep really drops down the re-excision rate,” says first author Judy Boughey, M.D., a breast surgeon in the Mayo Clinic Cancer Center. “Achieving negative margins in one operation has a huge impact on the patient’s satisfaction, decreases time away from work, time traveling back and forth to hospital appointments, and the financial cost to the patient, the insurance company and the hospital for a second operation.”
Mayo researchers compared 30-day reoperation rates for breast cancer lumpectomy patients at Mayo Clinic in Rochester with the reoperation rates for such patients at hospitals nationally as reported in American College of Surgeons National Surgical Quality Improvement Program data from 2006-10.
Patients in the national data were roughly four times likelier to undergo reoperation as those at Mayo in Rochester. The 30-day reoperation rate after lumpectomy for cancer was 13.2 percent nationally and 3.6 percent at Mayo in Rochester, the analysis found.
Unlike mastectomy — breast removal — a breast cancer lumpectomy typically preserves enough breast tissue to achieve an acceptable cosmetic result. Most women diagnosed with breast cancer have a choice between a lumpectomy and a mastectomy. However, women who have a lumpectomy and later learn another operation is needed to obtain negative margins may decide to get a mastectomy at that point, Dr. Boughey says.
The study’s senior author is Elizabeth Habermann, Ph.D., associate scientific director of the Surgical Outcomes Program in the Mayo Clinic Kern Center for the Science of Health Care Delivery. Mayo Clinic funded the research.
Sharon Theimer | EurekAlert!
Live imaging reveals how wound healing influences cancer
01.07.2015 | EMBO
Using bacterial 'fight clubs' to find new drugs
30.06.2015 | Vanderbilt University
New technique combines electron microscopy and synchrotron X-rays to track chemical reactions under real operating conditions
A new technique pioneered at the U.S. Department of Energy's Brookhaven National Laboratory reveals atomic-scale changes during catalytic reactions in real...
Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and a half billion years ago.
Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and...
A team of scientists including PhD student Friedrich Schuler from the Laboratory of MEMS Applications at the Department of Microsystems Engineering (IMTEK) of...
The three-year clinical trial results of the retinal implant popularly known as the "bionic eye," have proven the long-term efficacy, safety and reliability of...
On June 23, the second Sentinel mission was launched from the space mission launch center in Kourou. A critical component of Aachen is on board. Researchers at the Fraunhofer Institute for Laser Technology ILT and Tesat-Spacecom have jointly developed the know-how for space-qualified laser components. For the Sentinel mission the diode laser pump module of the Laser Communication Terminal LCT was planned and constructed in Aachen in cooperation with the manufacturer of the LCT, Tesat-Spacecom, and the Ferdinand Braun Institute.
After eight years of preparation, in the early morning of June 23 the time had come: in Kourou in French Guiana, the European Space Agency launched the...
25.06.2015 | Event News
16.06.2015 | Event News
11.06.2015 | Event News
01.07.2015 | Ecology, The Environment and Conservation
01.07.2015 | Materials Sciences
01.07.2015 | Materials Sciences